Our products help improve medical care for people with chronic diseases globally.

We want to serve the largest possible number of medical indications in order to make the lives of those affected easier. Thus, not only our company, but also society benefits from our growth strategy. This is because products for self-medication and services for improving the success of therapy optimise the therapies of chronically ill people and thus significantly relieve the burden on the healthcare system. Our ambition is to enable people to access self-medication and medical care. We are also pursuing this ambition through through growth, which enables us to reach more people with our injection devices for safe and easy self-medication. Because self-medication fundamentally facilitates and improves the possibilities of medical care. The formulation of innovative medicines for subcutaneous injection, instead of intravenous infusion, enables self-treatment for more and more indications. And the use of generic versions of expensive original preparations or so-called biosimilars makes therapy more affordable and thus accessible to a larger group of patients.

Our contribution

  • Establishing as a global provider of self-medication
  • Access to innovative medicines and biosimilars
  • Improving patients’ quality of life

Sustainable development goals (SDGs)

Gesundheit und Wohlergehen Menschenwürdige Arbeit und Wirtschaftswachstum Industrie, Innovation und Infrastruktur

Highlights 2021/22

  • 1.6 million people more reached with Ypsomed products totalling at 8.0 million and thus coming already very close to the target of 10 million users
  • Access to eight more biosimilars enabled and thereby contributing to an affordable healthcare system
  • First YpsoMate 2.25 Pro for high viscosity drug delivery
  • Another 36 new projects orders in the pen business for important indications

Learn more about our Access and Expansion ambitions in the annual report (PDF).

Latest news

Our expansion plans for future success

In 2019, our new production plant was opened in Schwerin in north-eastern Germany. Since then, we have been steadily expanding the plant capacities for our infusion and injection business. The Schwerin site supports our global growth ambitions and provides the production space and technical infrastructure for our medium to long-term growth. With this plant, we are planning for the future in order to always be able to reliably respond to the demand of our customers and partners.